Condition
Neuroendocrine (NE) Tumors clinical trials and research
As of November 12, 2026, Find a Trial lists 6 Neuroendocrine (NE) Tumors clinical trials that are recruiting, at sites in 10 countries (most in Italy (2), Sweden (2), Switzerland (2)). 1 was first registered in the last 30 days. By phase: Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 6Clinical trials
- 1New in 30 days
- 10Countries
Newest Neuroendocrine (NE) Tumors clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| External validation of the TB-NET score in advanced well‑differentiated neuroendocrine tumors | — | Boston, Massachusetts and 10 other locations | Recruiting | Oct 29, 2026 |
| Ultralow-dose PET imaging of somatostatin receptor 2 (SSTR2) uptake | Phase 2 | Englewood, New Jersey | Recruiting | Dec 16, 2025 |
| How endocrine tumors develop resistance to alkylating chemotherapy | — | Uppsala | Recruiting | Aug 14, 2025 |
| Quality of life after surgery for neuroendocrine tumors | — | Toronto, Ontario | Recruiting | May 20, 2025 |
| Removal of the primary small-intestine neuroendocrine tumor versus systemic therapy alone | — | Bern | Recruiting | Jan 22, 2025 |
| Using advanced imaging to detect small bowel neuroendocrine tumors | — | Milan | Recruiting | Jan 14, 2025 |
All recruiting trials (6)
-
External validation of the TB-NET score in advanced well‑differentiated neuroendocrine tumors
This study tests whether the TB-NET score can predict progression-free survival in adults with advanced well-differentiated gastroenteropancreatic neuroendocrine tumors or lung carcinoids who have received systemic therapy.
-
Ultralow-dose PET imaging of somatostatin receptor 2 (SSTR2) uptake
This study will test whether an ultralow-dose 68Ga-Dotatate PET scan on a high-sensitivity scanner can detect SSTR2 uptake in adults with and without neuroendocrine tumors.
-
How endocrine tumors develop resistance to alkylating chemotherapy
This study will test whether patients with endocrine tumors who receive alkylating chemotherapy develop high tumor mutation rates and whether blood tests and imaging can detect those changes.
-
Quality of life after surgery for neuroendocrine tumors
This study looks at how surgery for neuroendocrine tumors affects the quality of life for patients to help improve their care after the operation.
-
Removal of the primary small-intestine neuroendocrine tumor versus systemic therapy alone
This project tries to see if removing the main small-intestine neuroendocrine tumor helps people with incurable metastatic disease live longer or avoid future problems, compared with treating them with systemic therapy alone.
-
Using advanced imaging to detect small bowel neuroendocrine tumors
This study is testing a new imaging method to see if it can better find small bowel neuroendocrine tumors in patients, helping doctors decide on the best treatment.
Related topics
Quick answers
How many Neuroendocrine (NE) Tumors clinical trials are recruiting right now?
6, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 10 countries. The most sites are in Italy (2 trials), Sweden (2 trials), Switzerland (2 trials), United States (2 trials), Canada (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.